-
公开(公告)号:US11926612B2
公开(公告)日:2024-03-12
申请号:US16341597
申请日:2017-10-11
IPC分类号: C07D233/90 , C07D249/10 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/12 , C07D417/14
CPC分类号: C07D401/12 , C07D233/90 , C07D249/10 , C07D401/04 , C07D401/14 , C07D403/12 , C07D417/14
摘要: This disclosure is directed to agonists of the apelin receptor (APJ) with heterocyclic cores and uses of such agonists.
-
公开(公告)号:US20220387395A1
公开(公告)日:2022-12-08
申请号:US17631886
申请日:2020-07-27
发明人: Arthur T. SANDS , Neil F. BENCE , Christoph W. ZAPF , Frederick COHEN , Chenbo WANG , Thomas CUMMINS , Hiroko TANAKA , Morgan LAWRENZ , Mario CARDOZO , Dahlia WEISS , Jennifa GOSLING
IPC分类号: A61K31/4196 , C07D249/10 , C07D249/08 , C07D405/06 , C07D498/20 , C07D401/12 , C07D403/12 , C07D471/04 , C07D498/04 , C07D401/14 , C07D471/20 , C07D487/04 , C07D405/14 , C07D413/12 , C07D413/14 , C07D471/10 , C07D491/107 , C07D487/10 , C07D498/10 , C07D417/12 , C07F5/02 , A61K38/17 , A61K35/17 , A61K39/395 , A61K31/704 , A61K31/427 , A61K31/407 , A61K38/14 , A61K31/473 , A61K31/7048 , A61K31/136 , A61K31/351 , A61K38/12 , A61K31/4995 , A61K31/337 , A61K38/08 , A61K31/437 , A61K31/439 , A61K31/7072 , A61K31/513 , A61K31/706 , A61K31/7068 , A61K31/519 , A61K31/7076 , A61K31/52 , A61K31/517 , A61K31/655 , A61K31/495 , A61K31/496 , A61K31/047 , A61K31/336 , A61K31/66 , A61K31/7028 , A61K31/155 , A61K31/396 , A61K31/10 , A61K31/4184 , A61K31/573 , A61K31/131 , A61K31/137 , A61K33/243 , A61K31/282 , A61P35/00 , A61K31/5386 , A61K31/4439 , A61K31/4709 , A61K31/4375 , A61K31/5383 , A61K31/444 , A61K31/501 , A61K31/5377 , A61K31/4985 , A61K31/422 , A61K31/506 , A61K31/438 , A61K31/537 , A61K31/635 , A61K31/541 , A61K47/54 , C12N5/0783 , C12N15/62 , C12N15/86
摘要: Compounds of formulae (I) and (II), compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo.
-
公开(公告)号:US20220024926A1
公开(公告)日:2022-01-27
申请号:US17299890
申请日:2019-12-06
申请人: The United States Of America,As Represented By The Secretary,Department Of Health And Human Services
IPC分类号: C07D473/40 , C07D471/04 , C07D249/10
摘要: Disclosed are compounds of the formulas (I), (II), and (II): which are A1 adenosine receptor agonists, pharmaceutical compositions comprising such compounds, and a method of use of these compounds, wherein Y, R1-R6, R10-R15, and R20-R22 are as defined in the specification. These compounds are selective to the A1 adenosine receptor, and are contemplated for use in the treatment or prevention of a number of diseases or conditions, for example, for inducing and/or maintaining a hypothermic and/or hypometabolic state for treatment of a mammal.
-
公开(公告)号:US11072589B2
公开(公告)日:2021-07-27
申请号:US17067721
申请日:2020-10-11
申请人: SOOCHOW UNIVERSITY
发明人: Haiyan Li , Huihuang Li , Yaxiong Wang , Xiaobing Wan
IPC分类号: C07D249/10 , B01J23/72
摘要: A method for preparing 1,2,4-triazole includes using a fluoroborate aryl diazonium salt, a diazoester derivative and an organic nitrile as reaction substrates, a transition metal salt as a catalyst, and an inorganic base as an additive in a cyclization reaction. The method has the following characteristics: the reaction is economical; the substrate is universal; the post-functionalization is easy; the reaction conditions are mild; the reaction can be performed in air; the catalyst amount used is less; and the post-treatment is simple. Meanwhile, the raw materials, such as the reactants and the catalyst used, are inexpensive and easily available; the reaction composition is reasonable; no ligand is needed; there are less reaction steps; and only one step of reaction is required to obtain a high yield, meeting the requirements and directions of contemporary green chemistry and medicinal chemistry, being suitable for screening highly active 1,2,4-triazole drugs.
-
公开(公告)号:US20210179577A1
公开(公告)日:2021-06-17
申请号:US16759970
申请日:2018-10-24
发明人: Peter HAUFF , Stefan WERNER
IPC分类号: C07D401/04 , C07D231/12 , C07D213/61 , C07D231/16 , C07D249/10 , A61P9/10
摘要: A compound of formula (I) or an N-oxide, a salt, a hydrate, a solvate, a tautomer or a stereoisomer of said compound, or a salt of said N-oxide, tautomer or stereoisomer for use in the treatment or prophylaxis of brain ischemia, ischemic brain injury, Ischemic Stroke (IS), haemorrhagic stroke, traumatic brain injury, spinal cord injury.
-
公开(公告)号:US11022880B2
公开(公告)日:2021-06-01
申请号:US16160297
申请日:2018-10-15
发明人: Akiya Kawaue , Yuta Yamamoto , Kazuaki Ebisawa , Yasushi Kuroiwa
IPC分类号: G03F7/004 , G03F7/039 , G03F7/38 , G03F7/16 , G03F7/32 , C07D493/08 , C07C323/61 , G03F7/20 , G03F7/40 , C07D307/93 , C07D249/12 , C07C323/62 , C07D249/10 , C07D249/06 , C07C321/22 , C07D495/08 , C07C321/24
摘要: A chemically amplified positive-type photosensitive resin composition capable of suppressing the occurrence of “footing” in which the width of the bottom (the side proximal to the surface of a support) becomes narrower than that of the top (the side proximal to the surface of a resist layer) in the nonresist portion; and the generation of development residue when a resist pattern serving as a template for a plated article is formed on a metal surface of a substrate using the photosensitive resin composition. A mercapto compound having a specific structure is included in the photosensitive resin composition, and includes an acid generator which generates acid upon exposure to an irradiated active ray or radiation, and a resin whose solubility in alkali increases under the action of acid.
-
公开(公告)号:US20200345727A1
公开(公告)日:2020-11-05
申请号:US16761390
申请日:2018-11-02
发明人: Kathleen Ann Martin , Carmela Sidrauski , Jennifer M. Frost , Marina Pliushchev , Yunsong Tong , Lawrence A. Black , Xiangdong Xu , Lei Shi , Qingwei I. Zhang , SeungWon Chung , Ramzi Farah Sweis , Michael J. Dart , John T. Randolph , Kathleen J. Murauski
IPC分类号: A61K31/4965 , A61K45/06 , C07D261/18 , C07D263/34 , C07D241/20 , A61K31/421 , A61K31/42 , A61K31/437 , C07D471/04 , C07D487/04 , C07D333/38 , C07D307/68 , A61K31/381 , A61K31/519 , A61K31/341 , A61K31/415 , A61K31/426 , A61K31/425 , C07D275/03 , C07D277/56 , C07D231/14 , C07D495/04 , A61K31/4985 , C07D237/20 , C07D413/04 , C07D285/06 , C07D317/46 , A61K31/36 , A61K31/4245 , A61K31/422 , A61K31/4196 , C07D249/10 , C07D217/26 , A61K31/472 , A61K31/196 , C07C233/62 , C07D401/04 , A61K31/4427 , A61K31/5355
摘要: Provided herein are compounds, compositions, and methods useful for modulating the integrated stress response (ISR) and for treating related diseases; disorders and conditions.
-
公开(公告)号:US20200288710A1
公开(公告)日:2020-09-17
申请号:US16084159
申请日:2017-03-08
发明人: Martin FÜßLEIN , Heinz-Juergen WROBLOWSKY , Susanne KÜBBELER , Dominik HAGER , Nina KAUSCH-BUSIES , Klaus-Helmut MÜLLER , Daniela PORTZ , Kerstin ILG , Olga MALSAM , Sascha EILMUS , Peter LÖSEL , Ulrich GÖRGENS , Stefan HERRMANN , Angela BECKER
IPC分类号: A01N43/50 , C07D233/90 , C07D249/10 , A01N43/653 , C07D231/14 , A01N43/56 , C07D403/12 , C07D409/12 , C07D401/12 , C07D401/04 , C07D413/12 , A01N43/80
摘要: The present invention relates to the use of a compound of the general formula (I) in which M and D have the meanings given in the description for controlling animal pests.
-
公开(公告)号:US20190077773A1
公开(公告)日:2019-03-14
申请号:US16129199
申请日:2018-09-12
申请人: NOVARTIS AG
发明人: Natalie DALES , Paul GORMISKY , John Ryan KERRIGAN , Lei SHU
IPC分类号: C07D249/10 , C07D405/10 , C07D403/10 , C07D401/10 , C07D401/14 , C07D413/10 , C07D231/14 , A61P21/00 , A61P25/28 , A61P17/02 , A61P27/16
摘要: The present disclosure provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, and its therapeutic uses for activating a growth factor pathway, promoting wound healing, promoting tissue repair, and treating hearing loss, skeletal muscle loss, organ degeneration, tissue damage, neurodegeneration, and muscular atrophy. The disclosure further provides pharmaceutical compositions and combinations. The present disclosure also relates to the use of such compounds for research or other non-therapeutic purposes.
-
公开(公告)号:US10160731B2
公开(公告)日:2018-12-25
申请号:US15946601
申请日:2018-04-05
发明人: Gary David Annis
IPC分类号: C07D261/04 , C07C17/35 , C07C45/45 , C07C45/70 , C07C49/80 , C07C49/813 , C07C67/343 , C07C205/45 , C07C209/74 , C07C231/12 , C07C235/84 , C07D213/40 , C07D231/12 , C07D231/14 , C07D231/16 , C07D249/08 , C07D249/10 , C07D277/28 , C07C25/13 , C07C231/14
摘要: Disclosed is a method for preparing a compound of Formula 1 wherein Q and Z are as defined in the disclosure comprising distilling water from a mixture comprising a compound of Formula 2, a compound of Formula 3, a base comprising at least one compound selected from the group consisting of alkaline earth metal hydroxides of Formula 4 wherein M is Ca, Sr or Ba, alkali metal carbonates of Formula 4a wherein M1 is Li, Na or K, 1,5-diazabicyclo[4.3.0]non-5-ene and 1,8-diazabicyclo[5.4.0]undec-7-ene, and an aprotic solvent capable of forming a low-boiling azeotrope with water. Also disclosed is a method for preparing a compound of Formula 2 comprising (1) forming a reaction mixture comprising a Grignard reagent derived from contacting a compound of Formula 5 wherein X is Cl, Br or I with magnesium metal or an alkylmagnesium halide in the presence of an ethereal solvent, and then (2) contacting the reaction mixture with a compound of Formula 6 wherein Y is OR11 or NR12R13, and R11, R12 and R13 are as defined in the disclosure. Further disclosed is a method for preparing a compound of Formula 7 wherein Q and Z are as defined in the disclosure, using a compound of Formula 1 characterized by preparing the compound of Formula 1 by the method disclosed above or using a compound of Formula 1 prepared by the method disclosed above.
-
-
-
-
-
-
-
-
-